Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 1999

View Archived Issues

Bayer describes new oxazolidinone antibacterials in recently issued patent

Dihydropyridines from Pfizer show excellent bradykinin-antagonist effects

New benzimidazoles useful in the treatment of diabetes and its complications under study at ADIR

9a-Azalides with potent antibacterial activity in development at Merck

Pharmacia & Upjohn describes new triazinic compounds with multiple pharmacological effects

AMPA receptor antagonists in the pipeline at Schering

Pharmacological characterization of fluodipine: a new selective bradycardic agent

New AIDS vaccine expected to begin clinical trials later this year

Ziagen introduced by Glaxo Wellcome as new HIV treatment option

Vanguard Medica and Elan seek regulatory approval of Miguard in the U.S.

Beneficial vascular effects of estrogen therapy in hypercholesterolemic postmenopausal women

NeuroSearch commences phase II clinical trials of potential antidepressant

Ilex Oncology adds Canadian trial site to intoplicine development

Phase I clinical trial commences in Germany for insomnia compound

IND for MRE-0470 approved by FDA

First NDA filing for Prevatac expected to be delayed

AxyS and Protein Design Labs enter drug discovery agreement

Nexell acquires most CellPro assets and forms new diagnostics division

Sonus and Abbott amend EchoGen agreements

Proteasome inhibitors show potential in inflammatory disorders

Coulter: Q4 and FY 1998 highlights

Titan completes private placement, updates R&D progress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...